Safety and usefulness of fluorescence imaging using methylene blue as a fluorophore in a Japanese population with hepatobiliary and pancreatic diseases: A phase I study

What Was Tested

Researchers studied Methylene blue (non-peptide stack partner) in this clinical trial, phase i publication.

The researchers aimed to evaluate the usefulness of MB fluorescence imaging in patients undergoing hepatobiliary and pancreatic surgery and the safety of intraoperative administration of MB in patients without methemoglobinemia.

Why It Was Studied

Methylene blue (MB) has been used to treat methemoglobinemia.

Recently, a fluorescence imaging technique using MB as a fluorophore was used in several region but still not in hepatobiliary and pancreatic surgery; thus, information on the safety of intraoperative fluorescence imaging using MB in a healthy Japanese population is lacking.

Who Took Part

Eighteen patients undergoing hepatobiliary and pancreatic surgery were enrolled.

The secondary endpoint was the safety of fluorescence imaging using MB in patients without methemoglobinemia.

How the Study Was Run

The researchers developed and used a fluorescence imaging system to visualize MB as fluorescence.

The fluorescence intensity of the blood vessels, tumors, liver, and intestine were measured.

The primary endpoint was the ability of the MB fluorescence imaging to visualize vessels and tumors with fluorescence.

What Was Measured

PubMed files the paper under topics including East Asian People, Methylene Blue, Neuroendocrine Tumors, Optical Imaging, Pancreatic Neoplasms, Digestive System Diseases and Intraoperative Period.

Author keywords: fluorescence imaging, hepatobiliary disease and pancreas disease.

What This Means in Plain Language

This is a clinical trial, phase i of Methylene blue (non-peptide stack partner).

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2023 (Journal of hepato-biliary-pancreatic sciences), a journal based in Japan.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.